化学
苯并咪唑
敌手
立体化学
整合素
药理学
组合化学
生物化学
受体
有机化学
医学
作者
Richard D. Carpenter,Mirela Andrei,Edmond Y. Lau,Felice C. Lightstone,Ruiwu Liu,Kit S. Lam,Mark J. Kurth
摘要
The cell surface receptor alpha 4 beta 1 integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.
科研通智能强力驱动
Strongly Powered by AbleSci AI